top of page

FierceBiotech: Meissa Raises $30M to Take RSV Vaccine into the Clinic

Meissa Vaccines has raised $30 million to advance a pipeline of vaccines to prevent viral respiratory infections. The series A equips Meissa to run phase 1 and 2 trials of a respiratory syncytial virus (RSV) vaccine while moving other candidates based on its synthetic biology technology toward the clinic.

Read the full article on FierceBiotech.


Commenting has been turned off.
bottom of page